Insulet (NASDAQ:PODD) Shares Sold Off by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insulet stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Insulet Stock Performance

Shares of NASDAQ PODD traded down $1.67 during midday trading on Wednesday, hitting $136.46. 131,531 shares of the company’s stock were exchanged, compared to its average volume of 1,383,380. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The firm has a market cap of $9.46 billion, a P/E ratio of 25.50, a PEG ratio of 1.10 and a beta of 1.11. The stock’s 50 day moving average price is $140.56 and its 200-day moving average price is $158.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm’s revenue was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently modified their holdings of the company. Elevation Wealth Partners LLC raised its position in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares in the last quarter. MV Capital Management Inc. bought a new position in Insulet during the fourth quarter worth about $29,000. Continuum Advisory LLC acquired a new stake in Insulet during the second quarter valued at approximately $46,000. Sound Income Strategies LLC boosted its holdings in Insulet by 4,620.0% during the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 231 shares in the last quarter. Finally, State of Wyoming boosted its holdings in Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PODD shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Canaccord Genuity Group decreased their target price on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Benchmark decreased their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, UBS Group lowered their target price on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $186.68.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.